Osteoporosis, Postmenopausal Clinical Trial
Official title:
Effect of Mechanical Loading on Radius Bone Density and Microarchitecture in Primary Hyperparathyroidism
The purpose of the study is to determine the effect of forearm exercise on forearm bone
density in post-menopausal women with or without primary hyperparathyroidism.
The investigators hypothesize that forearm exercise will increase forearm bone density in
patients with primary hyperparathyroidism more so than in patients without primary
hyperparathyroidism.
Status | Completed |
Enrollment | 12 |
Est. completion date | October 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 45 Years and older |
Eligibility |
Inclusion Criteria: Inclusion criteria for primary hyperparathyroidism group: 1. Primary hyperparathyroidism (defined by an elevated serum calcium and concomitantly elevated or inappropriately normal PTH) 2. Female sex, postmenopausal status for at least five years, ages 45-80 3. English- or Spanish-speaking 4. DXA T-score less than -1.0 at the one-third radius 5. Physically capable of exercise 6. 25-hydroxyvitamin D >20 ng/mL. The latter inclusion criterion will lead to the enrollment of some individuals whose vitamin D stores will not be frankly low. We feel, however, that it is better to study subjects in their usual state rather than replacing them with vitamin D which could add another variable that would further complicate this pilot study. Inclusion criteria for the osteopenic control: 1. Female sex, postmenopausal status for at least five years ages 45-80 2. English- or Spanish-speaking 3. DXA T-score less than -1.0 at the one-third radius 4. Physically capable of exercise 5. Normal serum calcium and PTH level 6. 25-hydroxyvitamin D >20 ng/mL Exclusion Criteria: 1. Men, premenopausal women, women less than age 45 or greater than age 80 2. Familial hypocalciuric hypercalcemia 3. Current or prior use of bisphosphonates (alendronate or risedronate (within 12 months), ibandronate (within 6 months), other bisphosphonate (2 years) 4. Current use of cinacalcet 5. Current or prior use of estrogen replacement therapy (within 2 years) 6. Planned parathyroidectomy (within one year) 7. Planned initiation of bisphosphonates 8. DXA T-score greater than -1.0 at the one-third radius 9. Cardiovascular disease or uncontrolled hypertension 10. Exercise-limiting pulmonary diseases 11. Malignancy other than non-melanomatous skin cancer or microscopic thyroid cancer (within 5 years) 12. Renal failure 13. Secondary hyperparathyroidism 14. Celiac disease 15. Physical/orthopedic disabilities and neurologic disorders or vasculopathies that would place the subjects at risk or limit their ability to perform exercise (eg. arthritis, carpal tunnel syndrome, rotator cuff injury, etc) 16. Moderate or high physical activity (category 2 or 3) as assessed by the IPAQ questionnaire. This latter exclusion criterion is a measure of baseline physical activity and looks to exclude those who would have a lower likelihood of benefit by baseline participation in an exercise program. 17. Protected individuals (institutionalized), prisoners, and any other prospective participant who might not be able to give voluntary informed consent. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Columbia University Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Columbia University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of subjects with improved bone mass and bone quality at the 1/3 radius | The primary outcome is proportion of subjects with improved bone mass and bone quality at the 1/3 radius over one year. | 1 year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03931109 -
Circulating miRNA in Primary Hyperparathyroidism
|
||
Not yet recruiting |
NCT03232476 -
Effect of Mechanical Loading With PTH on Cortical Bone
|
Phase 4 | |
Completed |
NCT02884401 -
Peri-implant Bone Changes in Post-menopausal Osteoporotic Women
|
N/A | |
Completed |
NCT00073190 -
Patient- and Physician-Based Osteoporosis Education
|
Phase 1 | |
Completed |
NCT00402441 -
Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
|
Phase 4 | |
Completed |
NCT03710889 -
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
|
Phase 3 | |
Completed |
NCT00010712 -
Effects of Black Cohosh on Menopausal Hot Flashes
|
Phase 2 | |
Recruiting |
NCT05058976 -
Romosozumab Use to Build Skeletal Integrity
|
Phase 4 | |
Active, not recruiting |
NCT05405894 -
Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
|
||
Recruiting |
NCT03337971 -
Nutritional Supplement and Bone Health in Post-Menopausal Women
|
N/A | |
Completed |
NCT03701113 -
Milk Protein and Bone Health in Postmenopausal Women
|
N/A | |
Completed |
NCT01381588 -
The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women
|
N/A | |
Completed |
NCT00383422 -
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
|
Phase 3 | |
Completed |
NCT00549965 -
Satisfaction and Compliance of Risedronate in PMO
|
Phase 4 | |
Completed |
NCT00035256 -
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
|
Phase 4 | |
Completed |
NCT01386281 -
Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
|
||
Completed |
NCT05266261 -
Use of Ibandronate in Diabetic Patients
|
N/A | |
Recruiting |
NCT04964388 -
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
|
Phase 2 | |
Active, not recruiting |
NCT03623633 -
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
|
Phase 4 | |
Recruiting |
NCT05575167 -
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
|